Income Before Tax
Pre-Tax Income
Pfizer Pre-Tax Income increased by 9.5% to $3.33B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 29.3%, from $4.72B to $3.33B. Over 2 years (FY 2021 to FY 2024), Pre-Tax Income shows a downward trend with a -42.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionIncome Before Tax
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
This provides a view of profitability that is not skewed by varying tax rates or one-time tax credits.
Detailed definition
A company's profits before the deduction of corporate income tax. It combines operating performance with non-operating f...
Peer comparison
Used to compare companies across different tax jurisdictions to see who generates more raw profit.
Metric ID:
is_income_before_taxHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.61B | $7.84B | $4.18B | $9.05B | $11.45B | $9.00B | $5.23B | $6.27B | $2.27B | -$3.35B | $3.42B | -$103.00M | $4.72B | $0.00 | $2.79B | $3.04B | $3.33B |
| QoQ Change | — | +18.6% | -46.6% | +116.4% | +26.5% | -21.4% | -41.9% | +19.9% | -63.8% | -247.7% | +202.1% | -103.0% | >999% | -100.0% | — | +9.3% | +9.5% |
| YoY Change | — | — | — | — | +73.2% | +14.9% | +25.1% | -30.7% | -80.2% | -137.2% | -45.4% | -104.5% | +240.7% | — | -18.6% | >999% | -29.3% |
Range-$3.35B – $11.45B
CAGR-15.7%
Avg YoY Growth+246.9%
Median YoY Growth-23.9%
Current Streak2 quarters growth
Pre-Tax Income at Other Companies
Frequently Asked Questions
- What is Pfizer's pre-tax income?
- Pfizer (PFE) reported pre-tax income of $3.33B in Q3 2025.
- How has Pfizer's pre-tax income changed year-over-year?
- Pfizer's pre-tax income decreased by 29.3% year-over-year, from $4.72B to $3.33B.
- What is the long-term trend for Pfizer's pre-tax income?
- Over 2 years (2021 to 2024), Pfizer's pre-tax income has grown at a -42.5% compound annual growth rate (CAGR), from $24.31B to $8.03B.
- What does pre-tax income mean?
- The total profit a company made before paying its income taxes.